SCHEMBL2509656

SCHEMBL2509656

CCCN1Cc2cc(OCc3cnccc3Oc3ccccc3)ccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 3/20 0.41
WDR77 Q9BQA1 3/20 0.41
ITGB3 P05106 2/20 0.41
ITGAV P06756 1/20 0.41
ADAM17 P78536 3/20 0.41
EGFR P00533 1/20 0.39
GRM1 Q13255 2/20 0.38
GRM5 P41594 2/20 0.38
ITGA2B P08514 1/20 0.38
F10 P00742 2/20 0.37
PTGS1 P23219 2/20 0.37
PTGS2 P35354 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2512685 0.89 ADAM17 (0.40) PRMT5WDR77ITGB3ITGAVADAM17
SCHEMBL2510033 0.87 EGFR (0.43) PRMT5WDR77ITGB3ITGAVADAM17
SCHEMBL2512573 0.83 ADAM17 (0.39) PRMT5WDR77ITGB3ADAM17EGFR
SCHEMBL2511394 0.79 KDM4C (0.38) ITGB3ITGAVGRM5PTGS1PTGS2
SCHEMBL2511076 0.76 PRMT5 (0.37) PRMT5WDR77ITGB3ITGAVADAM17
SCHEMBL2507478 0.76 ITGB3 (0.44) ITGB3ITGAVADAM17EGFRGRM1
SCHEMBL3638895 0.76 ADAM17 (0.42) PRMT5WDR77ITGB3ITGAVADAM17
SCHEMBL2512868 0.74 PRMT5 (0.42) PRMT5WDR77ITGB3ADAM17EGFR
SCHEMBL2511391 0.74 GRM5 (0.38) ITGB3ITGAVGRM1GRM5PTGS1
SCHEMBL2509809 0.73 PRMT5 (0.40) PRMT5WDR77ITGB3ADAM17ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664214-B2 Small molecule potentiators of metabotropic glutamate receptors I AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-04 US claimed
US-8664214-B2 Small molecule potentiators of metabotropic glutamate receptors I AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-04 US disclosed
US-20110245232-A1 NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I ABBOTT GMBH & CO. KG (DE) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245232-A1 NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I GRM3, GRIN2C, GRIN2B PRMT5 1226/4885WDR77 2121/4885ITGB3 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.